The collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease, and cardiomyopathies, diseases that affect the heart muscle.
Insitro will use its Virtual Human AI platform to combine large-scale human and cellular data with AI-enabled target identification and drug design to discover new drug candidates. AstraZeneca will be responsible for clinical development and regulatory processes, and will have exclusive worldwide rights to selected programmes.
BREAKING